Myriad Genetics, Inc.
- Open
- 5.85
- Day high
- 5.93
- Day low
- 5.55
- Prev close
- 5.85
- Volume
- 180K
- Mkt cap
- $524M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.6
- P/S
- 0.6
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$39K over the last 3 months (1 open-market buy, 1 sale)
- 🏛Institutions mixed (13F)
Myriad Genetics, Inc. (MYGN) is a Healthcare company listed on NASDAQ. The stock is up 10% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 1 sale (SEC Form 4).
Myriad Genetics, Inc. (MYGN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
MYGN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.06 | $-0.09 | -50.0% | $200M | -1.0% |
| Feb 23, 2026 | $-0.02 | $0.04 | +300.0% | $210M | +0.7% |
| Nov 7, 2024 | $0.02 | $0.06 | +215.8% | $213M | -0.1% |
| Feb 27, 2024 | $0.01 | $0.04 | +214.2% | $197M | +0.9% |
| Aug 3, 2023 | $-0.10 | $-0.08 | +20.0% | $184M | -1.9% |
| May 3, 2023 | $-0.19 | $-0.21 | -10.5% | $181M | +5.6% |
| Feb 28, 2023 | $-0.16 | $-0.12 | +25.0% | $178M | +4.9% |
| Nov 1, 2022 | $-0.06 | $-0.19 | -216.7% | $156M | -8.0% |
| Aug 4, 2022 | $0.01 | $0.04 | +300.0% | $179M | +4.9% |
| May 5, 2022 | $-0.05 | $-0.03 | +40.0% | $165M | +5.3% |
| Feb 24, 2022 | $-0.02 | $-0.02 | -14.3% | $161M | -1.3% |
| Nov 2, 2021 | $0.01 | $-0.02 | -300.0% | $167M | +0.6% |
MYGN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Donnelly Brian Jofficer: Chief Commerical Officer | Grant | 5,000 | $3.94 |
| Jun 12, 2026 | Raha Samraat S.director, officer: President and CEO | Grant | 3,542 | $3.94 |
| Jun 9, 2026 | Kumar Rashmidirector | Sell | 15,000 | $4.46 |
| Jun 5, 2026 | Dreismann Heinrichdirector | Grant | 59,701 | — |
| Jun 5, 2026 | Davis Mark Stevendirector | Grant | 59,701 | — |
| Jun 5, 2026 | Reitan Colleen Fdirector | Grant | 59,701 | — |
| Jun 5, 2026 | Skovronsky Danieldirector | Grant | 59,701 | — |
| Jun 5, 2026 | Bisaro Pauldirector | Grant | 59,701 | — |
| Jun 5, 2026 | Kumar Rashmidirector | Grant | 59,701 | — |
| Jun 5, 2026 | Newcomer Lee Nisleydirector | Grant | 59,701 | — |
| Jun 5, 2026 | Phanstiel S. Louisedirector | Grant | 59,701 | — |
| Jun 2, 2026 | Jampa Rajofficer: Chief Technology Officer | Grant | 251,889 | — |
| May 14, 2026 | Bisaro Pauldirector | Buy | 7,500 | $3.69 |
| May 4, 2026 | Donnelly Brian Jofficer: Chief Commerical Officer | Tax | 55,975 | $4.80 |
| Apr 15, 2026 | Verratti Markofficer: Chief Operating Officer | Tax | 1,069 | $4.91 |
Source: MYGN SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full MYGN insider & 13F page →Myriad Genetics, Inc. company profile
Overview
Myriad Genetics, Inc. (NASDAQ:MYGN) is a genetic testing and precision medicine company founded in 1991 and headquartered in Salt Lake City, Utah. The company went public in 1995 and has evolved from a research-focused genomics company into a commercial leader in molecular diagnostics. Myriad develops and commercializes genetic tests primarily in oncology, women's health, and mental health applications, serving healthcare providers and patients in the United States and internationally. The company has built its reputation on pioneering work in hereditary cancer testing, particularly BRCA gene analysis, and has expanded its portfolio through both internal development and strategic acquisitions.
Business
Myriad Genetics operates in the molecular diagnostics industry, which involves analyzing genetic material to provide information about disease risk, prognosis, and treatment selection. The company's tests examine DNA, RNA, and other genetic markers to help healthcare providers make more informed medical decisions for their patients. The company operates through three primary business segments: Hereditary Cancer Testing represents the company's largest and most established business, generating approximately 40-45% of total revenue. This segment includes the flagship MyRisk Hereditary Cancer Test, which analyzes multiple genes to assess an individual's risk of developing various hereditary cancers. The BRACAnalysis CDx test specifically examines BRCA1 and BRCA2 genes, which are associated with increased risk of breast and ovarian cancers. These tests help identify individuals who may benefit from enhanced screening, preventive measures, or specific targeted therapies. Women's Health and Prenatal Testing accounts for roughly 25-30% of revenue and includes several products designed for reproductive health. The Prequel Prenatal Screen is a non-invasive test that analyzes maternal blood to screen for chromosomal abnormalities in developing fetuses. The Foresight Carrier Screen helps prospective parents understand their risk of passing genetic conditions to their children. This segment has shown strong growth, with prenatal testing revenue increasing 24% over the trailing twelve months. Mental Health Pharmacogenomics, primarily through the GeneSight test, represents approximately 20-25% of revenue and has been the company's fastest-growing segment. GeneSight analyzes genetic variations that affect how patients metabolize psychiatric medications, helping clinicians select more appropriate treatments for conditions like depression, anxiety, and ADHD. This segment has demonstrated remarkable growth, with 34% revenue growth year-over-year. The company also offers oncology prognostic tests including Prolaris for prostate cancer and EndoPredict for breast cancer, which help determine the aggressiveness of tumors and guide treatment decisions. Myriad is developing new capabilities in Minimal Residual Disease (MRD) testing and liquid biopsy through its Precise Tumor and Precise Liquid platforms, acquired from Intermountain Precision Genomics.
Revenue model
Myriad Genetics generates revenue primarily through direct billing for genetic testing services. The company operates clinical laboratories that process genetic tests ordered by healthcare providers, with revenue recognized when tests are completed and results are delivered. The business model involves several key components: Test Service Revenue constitutes the vast majority of income, with the company charging healthcare providers, insurance companies, or patients directly for each genetic test performed. Pricing varies significantly by test type, ranging from hundreds to several thousand dollars per test. The company maintains contracts with major insurance payers and also offers patient assistance programs and direct-pay options. Customer Base consists primarily of healthcare providers including oncologists, obstetricians, psychiatrists, genetic counselors, and primary care physicians who order tests for their patients. The company serves both large health systems and individual practitioners, with an increasing focus on electronic medical record (EMR) integrations to streamline the ordering process. Several factors significantly impact Myriad's profitability margins. Payer Coverage and Reimbursement represents the most critical factor, as insurance coverage decisions directly affect revenue per test. The company faces ongoing challenges with payer policies, as demonstrated by UnitedHealthcare's recent policy change that could impact GeneSight revenue by an estimated $40 million annually. Test Volume and Mix affects margins since higher-priced tests like hereditary cancer panels generate better margins than commodity prenatal screens. Laboratory Efficiency through the company's "Labs of the Future" program aims to reduce per-test processing costs through automation and improved workflows. Competition and Market Dynamics influence pricing power, with the company benefiting from competitors exiting certain markets while facing pressure in others. Regulatory Changes such as FDA's Lab-Developed Test regulations could create barriers for smaller competitors while requiring compliance investments. Clinical Evidence and Guidelines from medical societies can expand or contract addressable markets, as seen with potential ACOG guideline changes for carrier screening that could significantly expand that market opportunity.
Competitive moat
Myriad Genetics possesses a moderate but potentially vulnerable competitive moat built on several key factors. The company's strongest defensive position lies in its clinical evidence and data repository, accumulated over decades of genetic testing. This extensive database of genetic variants and their clinical associations creates significant barriers for new entrants who would need years to build comparable datasets. The company's established payer relationships and reimbursement infrastructure also provide meaningful advantages, as navigating insurance coverage for genetic tests requires substantial expertise and established channels. However, Myriad's moat faces several significant challenges. The expiration of key BRCA gene patents in the mid-2010s opened its most profitable market to competition, leading to substantial market share losses and pricing pressure. The company's brand recognition and clinical reputation among healthcare providers remains strong, particularly in hereditary cancer testing, but this advantage has proven insufficient to prevent competitive erosion. Technological differentiation provides some protection, especially in newer areas like MRD testing and pharmacogenomics, where the company's analytical capabilities and clinical validation studies create temporary advantages. The regulatory expertise required to navigate FDA oversight of laboratory-developed tests also creates barriers, potentially favoring established players like Myriad over smaller competitors. The primary competitive threats come from large diagnostic companies with superior resources and scale, such as Quest Diagnostics and LabCorp, which can leverage their broader testing menus and distribution networks. Technology disruption from next-generation sequencing companies and AI-powered diagnostic platforms poses longer-term risks. Additionally, payer consolidation and cost pressures in healthcare create ongoing challenges to pricing power and market access. Overall, while Myriad maintains certain competitive advantages, its moat is not particularly wide or durable, requiring continuous innovation and execution to maintain market position.
Risks & safety
Myriad Genetics presents a moderate margin of safety with mixed financial health indicators and reasonable valuation metrics. • Liquidity Position: Strong with $99.9 million in cash and short-term investments, current ratio of 1.90, and quick ratio of 1.73 • Debt Levels: Conservative debt-to-equity ratio of 0.20, indicating low financial leverage and manageable debt burden • Cash Flow: Concerning free cash flow of -$5.6 million in Q3 2024, though operating cash flow turned slightly positive at $0.7 million • Profitability: Company remains unprofitable with net loss of $22.1 million in Q3 2024, though showing improvement in adjusted EBITDA trends • Valuation Metrics: Trading at 3.4x book value and negative EV/EBITDA due to minimal EBITDA generation • Revenue Stability: Solid 11% revenue growth trajectory with diversified testing portfolio reducing single-product risk • Payer Risk: Significant exposure to insurance policy changes, as demonstrated by potential $40 million revenue impact from UnitedHealthcare policy modification • Other Considerations: FDA regulatory changes could benefit established players; market share recovery opportunities in hereditary cancer testing; strong balance sheet provides runway for strategic investments and product development
Recent development
Over the past few years, Myriad Genetics has executed several strategic pivots to diversify its business and reduce dependence on hereditary cancer testing. The company's most significant move was the acquisition of Intermountain Precision Genomics, which brought the Precise Tumor and Precise Liquid testing platforms and positioned Myriad to enter the growing liquid biopsy and minimal residual disease (MRD) testing markets. This acquisition represents a major expansion into oncology monitoring and treatment selection beyond the company's traditional risk assessment focus. The company has aggressively expanded its mental health pharmacogenomics business through GeneSight, which has become the fastest-growing segment with 34% year-over-year revenue growth. Management has invested heavily in digital marketing, EMR integrations, and payer relations to drive adoption among psychiatrists and primary care providers. However, this growth faces a significant challenge from UnitedHealthcare's policy change that could reduce revenue by $40 million annually. Women's health and prenatal testing has emerged as another growth driver, with the company launching new products like Foresight Universal Plus carrier screening and preparing to launch Prequel NIPS testing at eight weeks gestation. The segment has achieved 24% revenue growth over the trailing twelve months, benefiting from market share gains and expanded test offerings. Myriad has implemented its "Labs of the Future" program to improve operational efficiency and reduce costs through automation and workflow optimization. The company has also prioritized EMR integrations, targeting 4,000 new provider sites this year to streamline test ordering and improve customer experience. Additionally, the company has reorganized its European operations and divested non-core assets like the EndoPredict business to focus resources on higher-growth opportunities in the U.S. market. Looking forward, the company is preparing for the commercial launch of MRD testing in the first half of 2026, conducting research collaborations with major cancer centers to validate the clinical utility of its Precise MRD platform for monitoring treatment response and detecting cancer recurrence.
MYGN company profile · for informational purposes only — not investment advice.
Track MYGN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free